JEPI vs XBI
JPMorgan Equity Premium Income ETF vs SPDR S&P Biotech ETF
- • JEPI pays a higher dividend yield (8.11%).
Side-by-side metrics
| Metric | JEPI | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.35% | 0.35% |
Dividend yield Trailing 12-month yield. | 8.11% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $44.75B | $10.73B |
YTD return | 2.87% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.43 | 1.10 |
P/E ratio | 26.88 | — |
Last price | $56.64 | $164.01 |
Inception | — | — |
Issuer | JPMorgan | State Street |
JEPI top holdings
| ABBV | AbbVie Inc | 1.73% |
| HWM | Howmet Aerospace Inc | 1.69% |
| JNJ | Johnson & Johnson | 1.66% |
| ETN | Eaton Corp PLC | 1.63% |
| TT | Trane Technologies PLC Class A | 1.61% |
| LRCX | Lam Research Corp | 1.56% |
| NVDA | NVIDIA Corp | 1.52% |
| AAPL | Apple Inc | 1.52% |
| ROST | Ross Stores Inc | 1.51% |
| GOOGL | Alphabet Inc Class A | 1.51% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About JEPI
JEPI (JPMorgan Equity Premium Income ETF) is Active equity income with covered-call overlay. Managed by JPMorgan, the fund carries $44.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 8.11%. Its largest holding is AbbVie Inc (ABBV), which represents 1.7% of the portfolio. Real Estate is the fund's largest sector exposure at 3.2%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.